
The once-daily device, bioequivalent to the existing prefilled syringe, gives adults with AChR antibody-positive generalized MG a second self-injection option.
Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.
Patients with a longer disease duration and those with primary progressive MS were found to have higher rates of admission and longer hospital stays in this study from The American Journal of Managed Care.
To read the study in its entirety, follow






